FDA Approves First 3D-Printed Epilepsy Drug Experts Assess the Benefits and Caveats-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

FDA Approves First 3D-Printed Epilepsy Drug Experts Assess the Benefits and Caveats

Published:2015-09 Issue:18 Volume:15 Page:26-27
ISSN:1533-7006
Container-title:Neurology Today
language:en
Short-container-title:Neurology Today

Author:

Fitzgerald Susan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Clinical Neurology,Neurology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Life Cycle Assessment and Pharmaceutical Validations of Directly Compressed versus Additively Manufactured Tablets;Industrial & Engineering Chemistry Research;2024-05-08

2. Excipients in Pharmaceutical Additive Manufacturing: A Comprehensive Exploration of Polymeric Material Selection for Enhanced 3D Printing;Pharmaceutics;2024-02-24

3. Binder jetting 3D printing in fabricating pharmaceutical solid products for precision medicine;Basic & Clinical Pharmacology & Toxicology;2024-01-19

4. 3D-printed solid oral dosage forms for mental and neurological disorders: recent advances and future perspectives;Expert Opinion on Drug Delivery;2023-12-11

5. Polymers for Pharmaceutical 3D Printing: Printability and Critical Insight into Material Properties;3D Printing;2023-12-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP